Citations 1
Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Sims, Emily K. , Bundy, Brian N. , Stier, Kenneth , Serti, Elisavet , Lim, Noha , Long, S. Alice , Geyer, Susan, Moran, Antoinette , Greenbaum, Carla J. , Evans‐Molina, Carmella , Group, Type 1 Diabetes TrialNet Study, DiMeglio, Linda A. , Gitelman, Stephen E. , Gottlieb, Peter A. , Marks, Jennifer B. , Moore, Wayne D. , Rodriguez, Henry , Russell, William E. , Schatz, Desmond , Wherrett, Diane K. , Ziegler, Anette‐Gabriele , Herold, Kevan C , DiMeglio, Linda , Group, Type 1 Diabetes TrialNet Study, Moore, Wayne, Tsalikian, Eva
Science Translational Medicine | March 3, 2021 | Volume: 13 | Issue: 583 | Pages: No page available
Teplizumab treatment of nondiabetic relatives at high risk for T1D induces partially exhausted CD8 + T cells and improves beta cell function.